Dostarlimab

Dostarlimab (TSR-042, WBP-285) (INN) is a monoclonal antibody designed for the treatment of cancer.[1][2]

Dostarlimab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetPCDP1
Clinical data
Other namesTSR-042, WBP-285
Drug classAntineoplastic
ATC code
Identifiers
CAS Number
PubChem SID
UNII
KEGG
Chemical and physical data
FormulaC6420H9832N1690O2014S44
Molar mass144325.73 g·mol−1

Like several other available and experimental monoclonal antibodies, it is a PD-1 inhibitor. As of 2020, it is undergoing Phase I/II and Phase III clinical trials.[3][4][5] The manufacturer, Tesaro, announced prelimary successful results from the Phase I/II GARNET study.[3][6][7]

In 2020, the GARNET study announced that Dostarlimab was demonstrating potential to treat a subset of women with recurrent or advanced endometrial cancer.[8]

As of August 2020, Dostarlimab is not yet approved for any use, though license applications were filed with the FDA and EMA in early 2020.[9]

References
  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Dostarlimab, American Medical Association.
  2. World Health Organization (2018). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 119" (PDF). WHO Drug Information. 32 (2).
  3. Clinical trial number NCT02715284 for "A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (GARNET)" at ClinicalTrials.gov
  4. Clinical trial number NCT03981796 for "A Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)" at ClinicalTrials.gov
  5. Clinical trial number NCT03602859 for "A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)" at ClinicalTrials.gov
  6. "Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer". Tesaro (Press release). Retrieved 1 January 2020.
  7. Scalea B (28 May 2019). "Dostarlimab Effective in Endometrial Cancer Regardless of MSI Status". Targeted Oncology. Retrieved 1 January 2020.
  8. "GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer - Drugs.com MedNews". Drugs.com. Retrieved 29 April 2020.
  9. "AnaptysBio Announces First Quarter 2020 Financial Results and Provides Pipeline Updates". GlobeNewsWire. 6 May 2020. Retrieved 17 August 2020.
  • "Dostarlimab". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.